REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a [...]
About Shelly MamanThis author has not yet filled in any details.
So far Shelly Maman has created 8 blog entries.
Proceeds to enable the advancement of lead product candidate [...]
Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast Cancer
Ongoing Phase 2 ACCURACY study to explore AL101 and [...]
FDA Grants Orphan Drug Designation to Ayala’s AL101 for Potential Treatment of Adenoid Cystic Carcinoma (ACC)
ACC is a rare form of malignant cancer with [...]
Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma
Results support the clinical development of AL101 as a [...]
Ayala Pharmaceuticals Signs Deal to Develop and Commercialize AL102 in Combination with BCMA Targeting Agents in Multiple Myeloma
Licensing agreement includes equity investment and potential development, clinical, [...]
Ayala Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study of Lead Product Candidate AL101 for Adenoid Cystic Carcinoma with Notch Activated Mutations
Company aims to demonstrate the value of investigational pan-Notch [...]
Ayala Pharmaceuticals Presents Phase 1b Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting for AL101, a Pan-Notch Inhibitor, in Patients with Locally Advanced or Metastatic Solid Tumors
Positive Results Support Development Pathway of AL101 as a [...]